BTIG Fall Biotechnology Conference

BTIG Biotechnology Analysts Tim Chiang, Robert Hazlett, Amanda Murphy, CFA and Thomas Shrader, PhD, CFA hosted the “BTIG Fall Biotechnology Conference” in New York on Thursday, October 25, 2018.  The format of the conference included one-on-one meetings and panel discussions led by the BTIG Biotechnology team, key opinion leaders and panelists from emerging private and established multinational biotechnology companies.

The private conference was open to BTIG’s institutional investor clients and covered key issues which impact biotechnology companies today. Panel discussion topics included New Treatments in Duchenne Muscular Dystrophy / Limb-Girdle Muscular Dystrophy; Gene Therapy: The Next Wave of Innovation; Targeted Oncology Therapies: Material Advancements, Intriguing Potential; Immuno-Oncology in Solid Tumors: What’s After PD1s?; Immuno-Oncology in Liquid Tumors: Where is the Unmet Need?; Therapeutic Advancements for CNS Disorders; and Topics in Metabolic Diseases: from T2D to Anemia and NASH.

Key opinion leaders that attended the conference included:

  • Richard A. Friedman, MD – Professor of Clinical Psychiatry, Director of the Psychopharmacology Clinic, and Director of the Fundamentals of Biological Psychiatry Curriculum in the Department of Psychiatry at Cornell University Medical College and New York Presbyterian Hospital.
  • Arun Jesudian, MD – Transplant Hepatologist at Weill Cornell Medicine, who specializes in the medical management of all types of liver disease including viral hepatitis B and C, alcoholic and nonalcoholic fatty liver disease (NAFLD), autoimmune liver disease, inherited and metabolic liver disorders, cirrhosis, and hepatocellular carcinoma.
  • Jerry R. Mendell, MD –  Attending neurologist at Nationwide Children’s, principal investigator in the Center for Gene Therapy at The Research Institute of Nationwide Children’s, Director of the Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, Co-Director of the Muscular Dystrophy Association Clinic, and Professor of Pediatrics, Neurology, Pathology, and Physiology and Cell Biology at The Ohio State University College of Medicine.
  • Stuart H. Packer, MD – Clinical Director of Medical Oncology at Montefiore-Einstein Center for Cancer Care and Associate Professor at Albert Einstein College of Medicine in New York.
  • Jae Park, MD – Assistant Attending Physician in the Division of Hematologic Oncology, Leukemia Service at Memorial Sloan Kettering Cancer Center in New York, NY.
  • Johannes van der Loo, PhD – Director of the Clinical Vector Core at the Center for Molecular & Cellular Therapeutics at The Children’s Hospital of Philadelphia and adjunct Associate Professor at the University of Pennsylvania.

To learn more about BTIG Corporate Access, click here.


This information was prepared for BTIG, LLC institutional clients. The information contained herein has been gathered from multiple sources and is believed to be reliable. However, BTIG, LLC has not independently verified the accuracy of the content and does not make any representations as to the accuracy or completeness of this information. The information is subject to change without notice and BTIG, LLC has no obligation to provide any updates or changes. BTIG, LLC is providing this data for informational purposes and does not believe that it is sufficient to base an investment decision on. This information should not be regarded as a solicitation or recommendation of any particular security or to engage in any trading strategy. BTIG, LLC does and may seek to do business, including investment banking and/or other capital markets business, with companies which are the subject of Corporate Access services.